---
title: "Octapharma receives FDA approval for new Fibryga formulation in AFD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271917281.md"
description: "Octapharma has received FDA approval for a new 2g formulation of Fibryga for patients with acquired fibrinogen deficiency (AFD). This new kit includes 100ml of Water for Infusion and the nextaro reconstitution device, enhancing preparation and dosing flexibility in urgent clinical settings. Fibryga is the only virus-inactivated, human plasma-derived fibrinogen concentrate approved for AFD in the US, providing a quicker alternative to traditional cryoprecipitate. The approval aims to improve outcomes for patients with serious bleeding complications."
datetime: "2026-01-08T10:07:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271917281.md)
  - [en](https://longbridge.com/en/news/271917281.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271917281.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271917281.md) | [繁體中文](https://longbridge.com/zh-HK/news/271917281.md)


# Octapharma receives FDA approval for new Fibryga formulation in AFD

The new kit contains 100ml Water for Infusion and includes the nextaro reconstitution device. Credit: Octapharma / PRNewswire.

Octapharma has received approval from the US Food and Drug Administration (FDA) for a new 2-gram (g) formulation of Fibryga for use in patients with acquired fibrinogen deficiency (AFD).

The approval offers healthcare providers with an additional option alongside the existing 1g version.

### Go deeper with GlobalData

-   ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png)
    
    Reports
    
    #### LOA and PTSR Model - Aldafermin in Constipation
    
-   ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png)
    
    Reports
    
    #### LOA and PTSR Model - Aldafermin in Liver Fibrosis
    

##### Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

#### Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The new kit contains 100ml Water for Infusion (WFI) and includes the nextaro reconstitution device, enabling streamlined preparation and increased dosing flexibility in urgent clinical settings.

Fibryga is said to be the sole virus-inactivated, human plasma-derived fibrinogen concentrate that received approval for AFD in the US.

Its lyophilised powder form enables quick reconstitution at the point of care, offering a substitute for cryoprecipitate, which has traditionally been used despite recognised limitations.

The expanded product line builds on Fibryga’s earlier FDA approval in 2024 for AFD. This approval was supported by the FIBRES study published in JAMA.

GlobalData Strategic Intelligence

# US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Learn more about Strategic Intelligence

Octapharma president Flemming Nielsen said: “The introduction of the 2g Fibryga kit is a direct response to the needs of clinicians managing critical bleeding. By simplifying preparation and expanding dosing flexibility, we’re helping providers act faster and more precisely – when every second counts.”

Octapharma medical affairs vice-president Huub Kreuwel said: “Octapharma continues to invest in innovations that improve outcomes for patients with serious bleeding complications. The new 2g Fibryga kit is another step forward in our mission to redefine the standard of care in haemostasis.”

Fibryga has received approval in the US for use as fibrinogen supplementation in patients with congenital as well as acquired fibrinogen deficiency.

Indications include supplementation for bleeding patients with acquired fibrinogen deficiency, as well as treatment of acute bleeding episodes in those with congenital fibrinogen deficiency, including afibrinogenaemia and hypofibrinogenaemia.

## Related News & Research

- [Hershey says it will shift back to classic recipe for all Reese's products after criticism](https://longbridge.com/en/news/281396136.md)
- [10:55 ETHost Defense® Expands MycoBenefits® Line with New Formulas Uniquely Designed for Women's Wellness*](https://longbridge.com/en/news/281545438.md)
- [08:37 ETSYNEVIT® Highlight: Quality, Transparency, and Education in the Nutraceutical Spotlight](https://longbridge.com/en/news/281188602.md)
- [Beyond Cheap Fish Oil: How A 5:1 DHA Ratio Powers Brain Health & Vision](https://longbridge.com/en/news/281264741.md)
- [08:43 ETLeaf & Mineral™ Celebrates National Cleaning Week with Focus on Innovative Cleaning Solutions](https://longbridge.com/en/news/281370110.md)